In an era of health reform, diagnostic technologies that focus on prevention and test the viability of expensive treatment options are becoming increasingly valuable to health providers, payers, and patients. Historically, investment in this sector has not seen the vigor demonstrated with medical devices or biotech innovations. However, in today’s environment, diagnostics are becoming attractive opportunities for companies looking for collaborations or acquisitions as well as investors looking for cutting-edge technologies, all creating a robust industry on the brink of breaking through to the mainstream.
In this presentation, panelists will:
- Provide insight on the diagnostic industry on a local and national level
- Discuss key elements that are reviewed when assessing start-up opportunities
- Discuss where opportunities exist for maximizing profits
- Provide new strategies for raising funds in this dynamic marketplace
Panelists:
Stephen DiPalma, Chief Financial Officer, Envivo Pharmaceuticals
Ronald S. Eppen, Partner, Foley & Lardner LLP
Mitchell Sanders, CEO and Founder, ECI Biotech
Related Insights
July 9, 2025
Manufacturing Industry Advisor
Foley Automotive Update
Analysis by Julie Dautermann, Competitive Intelligence Analyst Foley is here to help you through all aspects of rethinking your long-term…
July 9, 2025
Energy Current
ITC and PTC Changes Under the Big Beautiful Bill Act
President Trump last week signed into law the One Big Beautiful Bill Act (the “Act”). The Act made a number of changes to the clean…
July 9, 2025
Powered by Foley
Energy Industry Disputes
Whether we like it or not, there’s always a chance a dispute will arise during the lifespan of an energy project, which may only accelerate following changes to federal energy tax credits that could significantly upend parties’ commercial assumptions.